CEL-SCI

Historical price data

CEL-SCI is a long-standing, publicly-traded biotech focused on developing Multikine, a first-in-class neoadjuvant immunotherapy for advanced primary head and neck cancer. The company's core strategy is predicated on administering immunotherapy when the patient's immune system is most intact, a paradigm validated by a large, global Phase 3 trial that demonstrated a significant 14.1% absolute overall survival benefit in a key treatment arm. Having completed this pivotal study, CEL-SCI's primary objective is to secure regulatory approval via a BLA/NDA submission, aiming to establish a new standard of care in a significant unmet medical need.

Neoadjuvant, off-the-shelf cytokine immunotherapy (Multikine) and the LEAPS (Ligand Epitope Antigen Presentation System) platform for modulating immune responses in autoimmune and infectious diseases.

Multikine's primary competition is the current standard of care (surgery + radiation/chemo), as no other neoadjuvant immunotherapy is approved for this setting. However, large pharma companies are actively investigating checkpoint inhibitors in neoadjuvant regimens across oncology, posing a future competitive threat.